Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Commentary
  • Published:

In all, Wall Street supports biotech acquisitions

Bio/Technology volume 13, pages 729–730 (1995)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Author notes

  1. Fariba Fischel Ghodsian is vice president and biotechnology/phar-maceuticals analyst at Wedbush Morgan Securities (Los Angeles, CA). Darby Heidemann, a research assistant at Webush Morgan Securities, contributed to this commentary.

    • Fariba Fischel Ghodsian
Authors
  1. Fariba Fischel Ghodsian
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghodsian, F. In all, Wall Street supports biotech acquisitions. Nat Biotechnol 13, 729–730 (1995). https://doi.org/10.1038/nbt0895-729

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0895-729

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing